Orsini Specialty Pharmacy

Overview

Orsini Specialty Pharmacy is a rare disease and cell/gene therapy-focused specialty pharmacy operating an integrated model that combines specialty dispensing, hub services, and third-party logistics (3PL) under one platform. Founded in 1987 and acquired by the Carlyle Group and Consonance Capital Partners in May 2022, Orsini has carved a distinctive niche as the specialty pharmacy with the largest cell/gene therapy portfolio in the industry — 12 approved CGTs as of early 2026. (Source: raw/research/orsini-specialty-pharmacy.pplx.md)

Orsini generates an estimated $350-500M in revenue, holds 35+ limited distribution drug (LDD) designations, and maintains 50-state licensure. The company holds both URAC Rare Disease Center of Excellence and ACHC Distinction in Rare Diseases accreditations — one of only two specialty pharmacies nationally to hold both (alongside PANTHERx Rare).

The integrated hub+SP+3PL model is Orsini’s structural differentiator: manufacturers can consolidate specialty dispensing, patient support services, and physical distribution/cold chain logistics with a single partner, reducing complexity and improving data continuity across the patient journey.

Services & Capabilities

Specialty Pharmacy Dispensing

• 50-state licensure with national dispensing capabilities
• 35+ LDD designations across rare disease, cell/gene therapy, and specialty therapeutics
• Dual rare disease accreditations: URAC Rare Disease CoE + ACHC Distinction in Rare Diseases
• Specialized in ultra-rare and complex therapies requiring deep clinical expertise

Cell & Gene Therapy Center of Excellence

Orsini’s crown jewel — the largest CGT portfolio in the specialty pharmacy industry:

• 12 cell/gene therapies: Zolgensma, Elevidys, Roctavian, Hemgenix, LYFGENIA, ZYNTEGLO, SKYSONA, CASGEVY, KEBILIDI, ENCELTO, MACI
• Ultra-cold chain storage and just-in-time dispensing
• REMS compliance and treatment center coordination
• Long-term follow-up and outcomes tracking

Hub Services

Integrated hub services providing:

• Benefits investigation and prior authorization
• Patient enrollment and onboarding
• Financial assistance coordination (copay, PAP, foundation referrals)
• Adherence monitoring and clinical support
• Manufacturer reporting and analytics

Third-Party Logistics (3PL)

• Columbus, OH 3PL facility launched October 2025
• Ultra-cold storage capabilities for cell/gene therapies and temperature-sensitive biologics
• National distribution supporting manufacturer direct-to-patient and direct-to-site models
• Complements the SP and hub services with physical supply chain capabilities

DMD Exclusive Franchise

Orsini holds a unique position in Duchenne muscular dystrophy (DMD):

• All approved DMD therapies: Sarepta exon-skipping therapies + Elevidys (gene therapy)
• Deep clinical expertise in neuromuscular disease
• Longitudinal patient relationships across the DMD therapy lifecycle

Pulmonology / IPF

• 4 approved IPF (idiopathic pulmonary fibrosis) therapies
• 6,000+ IPF patients served
• Specialized clinical pharmacist teams for pulmonary disease management

Competitive Position

Orsini competes directly with PANTHERx Rare for ultra-rare disease manufacturer exclusives:

• CGT leadership: 12 cell/gene therapies vs PANTHERx Rare’s growing but smaller CGT portfolio (via RxARECONCIERGE). Orsini’s CGT depth is currently unmatched.
• Integrated model: Hub+SP+3PL under one roof is unique among rare disease-focused SPs. PANTHERx offers hub+SP but outsources logistics.
• Scale gap: Orsini ($350-500M est.) is significantly smaller than PANTHERx ($1B+) in total revenue, but may match or exceed on CGT-specific volume.
• PE backing: Carlyle/Consonance ownership (since May 2022) implies a 2027-2029 exit window, likely via sale to a larger SP or strategic acquirer.

Also competes with Accredo/Evernorth (GeneAXS team), BrightSpring/CareMed, and other specialty pharmacies seeking rare disease and CGT designations.

Recent Developments

• October 2025: Columbus, OH 3PL facility launched — adds ultra-cold storage and national distribution capabilities, strengthening the integrated hub+SP+3PL model.
• February 2026: Genetix gene therapies partnership announced covering 3 products, further expanding the CGT portfolio.
• March 2026: Secured Immedica LOARGYS exclusive distribution; Glaukos Epioxa single-source designation.
• January 2025: PicnicHealth partnership for real-world evidence (RWE) generation — enables longitudinal outcomes data from patient medical records with consent.
• ORBIT AI platform: Ongoing development of AI-driven analytics and RWE capabilities.

Client & Partner Ecosystem

Manufacturer Partners

• Sarepta Therapeutics: Full DMD franchise (exon-skipping + Elevidys)
• Novartis: Zolgensma (SMA gene therapy)
• BioMarin: Roctavian (hemophilia A gene therapy)
• CSL Behring: Hemgenix (hemophilia B gene therapy)
• bluebird bio: LYFGENIA, ZYNTEGLO, SKYSONA (gene therapies for SCD, beta-thalassemia, CALD)
• Vertex: CASGEVY (gene-edited therapy for SCD/beta-thal)
• Immedica: LOARGYS (exclusive, March 2026)
• Glaukos: Epioxa (single-source, March 2026)
• Genetix: 3 gene therapy products (February 2026)

Technology Partners

• PicnicHealth: RWE data generation from patient records (January 2025)

PE Owners

• Carlyle Group + Consonance Capital Partners: Acquired May 2022; likely 2027-2029 exit horizon

Technology Platform

ORBIT AI Platform

Orsini’s proprietary analytics and AI platform:

• Real-world evidence generation and reporting
• Patient journey analytics
• Manufacturer insights and therapy-level performance dashboards
• PicnicHealth integration for longitudinal outcomes data
• Predictive analytics for adherence and patient risk stratification

3PL Technology

• Ultra-cold chain monitoring and compliance (Columbus, OH facility)
• Inventory management for limited distribution and temperature-sensitive products
• Track-and-trace for cell/gene therapy shipments

Therapeutic Focus

Orsini’s therapeutic focus is heavily weighted toward rare disease and gene therapy:

• Cell & gene therapy: 12 approved therapies — the broadest CGT portfolio in the industry
• Neuromuscular disease: DMD franchise (all approved therapies), SMA
• Hematology: Hemophilia A & B (gene therapies), sickle cell disease (gene therapy + gene editing)
• Pulmonology: IPF (4 therapies, 6,000+ patients)
• Rare metabolic: Various orphan disease therapies
• Ophthalmology: Emerging (Glaukos Epioxa)

Sources

• Orsini Specialty Pharmacy research